Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Raynovent Logo
Raynovent Growth Score
21
CB Rank
91346
Heat Score
46
Raynovent is a science-driven innovative biotech company.
Founded
obfuscation
PrivateSeries C Guangzhou, Guangdong, China www.raynovent.com/
Biotechnology
Overview

Raynovent
Total Funding
obfuscation
Growth Score
21
Heat Score
46

Total Funding
obfuscation
obfuscation
Series C raised
obfuscation
Growth Score21
-3 pts
in past quarter
Heat Score 46
-14 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Raynovent

CB Rank
91346
Raynovent is a science-driven innovative biotech company.
Founded
obfuscation
PrivateSeries C Guangzhou, Guangdong, China www.raynovent.com/
Biotechnology

Funding Rounds

Series C
OBF
in
obfuscation
Series B
OBF
in
obfuscation
Series A
OBF
in
obfuscation

Details

Legal Name RAYNOVENT Co., Ltd.
Also Known As Guangdong Raynovent Biotech Co., Ltd.
Operating Status Active
Company Type For Profit
About the Company
Raynovent is a science-driven innovative biotech company.
Phone Number 020-31600199
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Laureatevir (来瑞特韦片)
An oral small molecule 3CL protease inhibitor drug for treating COVID-19, approved conditionally in China.
ZSP1273 (昂拉地韦片, Anrawei®)
An oral small molecule RNA polymerase PB2 inhibitor for treating and preventing Influenza A and avian influenza in adults.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C
obfuscation
Series C - Raynovent Logo
Series C - Raynovent
6
obfuscation
EFung Capital, Eide FundSeries C

Investors

Market Intelligence
People
View Profiles & Contacts
News

News and Press

News•Aug 22, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 10, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

235
-76.09%
 in past month

Active Website Tech Count

6Raynovent is actively using 6 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  Euro.

Total IP

42The intellectual property of Raynovent includes 42 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Raynovent's headquarters? Raynovent is located in Guangzhou, Guangdong, China.Who invested in Raynovent? Raynovent has 15 investors including Guangzhou Guoju Venture Capital and  Guangdong Zhongsheng Pharmaceutical.When was the last funding round for Raynovent? Raynovent closed its last funding round on
obfuscation
from a Series C round.Who are Raynovent's competitors? Alternatives and possible competitors to Raynovent may include Eli Lilly, Pfizer, and  BioAge Labs.How much funding has Raynovent raised to date? Raynovent has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|